Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

Prediction of Recurrence Among Low Risk Endometrial Cancer Population

This study investigates whether molecular testing can help to predict the risk of endometrial cancer coming back (recurrence) after treatment in patients diagnosed with low risk endometrial cancer and scheduled to have surgery to remove the uterus and/or cervix (hysterectomy). Having sentinel lymph node mapping performed may help researchers to see if the cancer has spread in patients with low risk endometrial cancer.

Study Overview

• Status: Active, not recruiting
• Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
• Intervention / Treatment: Other: Laboratory Biomarker Analysis; Procedure: Biospecimen Collection; Procedure: Bilateral Salpingectomy with Oophorectomy; Procedure: Hysterectomy; Procedure: Lymph Node Mapping; Procedure: Sentinel Lymph Node Biopsy

Detailed Description

PRIMARY OBJECTIVE:

I. Validate the use of a molecular panel of estrogen-induced genes to predict recurrence in low risk endometrial cancer.

SECONDARY OBJECTIVES:

I. Calculate the positive predictive value (PPV)/negative predictive value (NPV)/sensitivity (Sens)/specificity (Spec) of lymph node mapping to predict pelvic lymph node involvement.

II. Correlate CA125 and HE4 levels with recurrence and to explore the use of other serum biomarkers to predict recurrence.

III. Describe patterns of recurrence in a low risk patient population. IV. Determine if molecular panel can predict lymph node involvement in low risk endometrial cancer patients who undergo pelvic and para-aortic lymphadenectomy.

V. Compare performance of molecular panel to the Mayo low risk criteria for prediction of lymph node involvement.

VI. Compare performance of molecular panel to the high intermediate risk criteria from Gynecologic Oncology Group, trial 99 (GOG 99) for prediction of recurrence.

VII. Determine the feasibility of lymph node mapping in this patient population.

VIII. Determine the morbidity and mortality of lymph node dissection and mapping.

OUTLINE:

Patients undergo hysterectomy and sentinel lymph node mapping. Patients may also undergo bilateral salpingo-oophorectomy at the direction of the treating physician. If peritoneal disease or other contraindications to lymphatic mapping are detected at the time of surgery, mapping and sentinel node biopsy are performed at the surgeon's discretion. At the time of hysterectomy, patients undergo collection of tissue for molecular testing. Before and after surgery, patients also undergo collection of blood samples for tumor marker analysis.

• Study Type: Observational
• Enrollment (Actual): 518

Contacts and Locations

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • M D Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with low risk endometrial cancer who are scheduled to have a hysterectomy

Description

Inclusion Criteria:

• Histologically confirmed low grade (grade 1-2) endometrioid type adenocarcinoma
• Candidate for surgery
• No evidence of deep invasion or peritoneal disease in patients that have undergone preoperative imaging
• Patients may have had prior hormonal treatment for the treatment of early endometrial neoplasia. Patients may not have had prior radiation or chemotherapy for treatment of endometrial cancer
• Patients must have a negative pregnancy if of childbearing potential

Exclusion Criteria:

• Histologically confirmed high grade endometrioid or non-endometrioid type endometrial cancer (including serous, clear cell, carcinosarcoma or any mixed tumor containing these cell types)
• Medical co-morbidities making surgery unsafe, as determined by the primary treating physician
• Evidence of deep myometrial invasion, cervical involvement or peritoneal disease on preoperative imaging
• Prior treatment with radiation or chemotherapy for endometrial cancer
• Any contraindication to lymph node mapping

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Ancillary-Correlative (biospecimen collection, node mapping); Patients undergo hysterectomy and sentinel lymph node mapping. Patients may also undergo bilateral salpingo-oophorectomy at the direction of the treating physician. If peritoneal disease or other contraindications to lymphatic mapping are detected at the time of surgery, mapping and sentinel node biopsy are performed at the surgeon's discretion. At the time of hysterectomy, patients undergo collection of tissue for molecular testing. Before and after surgery, patients also undergo collection of blood samples for tumor marker analysis.

Other: Laboratory Biomarker Analysis; Correlative studies; Procedure: Biospecimen Collection; Undergo collection of blood and tissue samples; Procedure: Bilateral Salpingectomy with Oophorectomy; Undergo standard of care bilateral salpingo-oophorectomy; Other Names: bilateral salpingo-oophorectomy; Procedure: Hysterectomy; Undergo standard of care hysterectomy; Other Names: Hysterectomy NOS; Procedure: Lymph Node Mapping; Undergo sentinel lymph node mapping; Other Names: lymphatic mapping; Procedure: Sentinel Lymph Node Biopsy; Undergo sentinel lymph node biopsy; Other Names: Sentinel Node Biopsy; Sentinel node biopsy alone; SLNB; SNB

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
2-year recurrence	Will validate a model's ability to predict 2-year recurrence in low-risk endometrial cancer patients.	At 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Predictive ability of lymph node mapping in pelvic lymph node involvement	Will calculate the sensitivity (true positive fraction [TPF]), specificity (1-false positive fraction [FPF]), positive predictive value (PPV), and negative predictive value (NPV) of lymph node mapping in predicting pelvic lymph node involvement, along with 2-sided 95% confidence intervals.	Up to 2 years
Feasibility of lymph node mapping	Feasibility of lymph node mapping in this patient population will be determined after examining the TPF, FPF, PPV, and NPV.	Up to 2 years
Morbidity and mortality prevalence associated with lymph node dissection	Morbidity and mortality prevalence associated with lymph node dissection and mapping will be calculated with 95% confidence intervals.	Up to 2 years
Patterns of recurrence	Will determine which demographic and clinical traits are most associated with recurrence rate using proportional hazards models and with 2-year recurrence using logistic regression models. Will conduct univariate analyses using log-rank tests and Fisher's exact tests, in the case of categorical traits, and proportional hazards and logistic regression models, in the case of continuous traits. Will examine all traits for violations of the proportional hazards assumption (recurrence rate models), and will examine all continuous traits for functional form (recurrence and recurrence rate models). Will use the same methods to determine whether CA125 and HE4 is associated with recurrence and recurrence rate.	Up to 2 years
Predictive ability of molecular panel in lymph node involvement	Will use Cartesian and Regression Tree Analysis and logistic regression to determine if the molecular panel can predict lymph node involvement. Will assess the use of the model by calculating sensitivity, specificity, PPV, and NPV. Additionally, will examine how often the results of the molecular panel model concur with the Mayo low risk criteria for prediction of lymph node involvement. All agreement statistics will be presented with their 95% confidence intervals.	Up to 2 years
Predictive ability of marker panel in recurrence	Will examine how well the predictive ability of the marker panel agrees with the predictive ability of the high intermediate risk criteria from Gynecologic Oncology Group, trial 99 using this patient population. 95% confidence intervals will be calculated for all concordance statistics.	Up to 2 years

Collaborators and Investigators

• Sponsor: M.D. Anderson Cancer Center
• Investigators: Principal Investigator: Shannon N Westin, M.D. Anderson Cancer Center

Publications and helpful links

Helpful Links

• MD Anderson Cancer Center Website

Study record dates

Study Major Dates

• Study Start (Actual): November 8, 2012
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: October 21, 2020
• First Submitted That Met QC Criteria: October 21, 2020
• First Posted (Actual): October 27, 2020

Study Record Updates

• Last Update Posted (Actual): March 9, 2026
• Last Update Submitted That Met QC Criteria: March 5, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Endocrine System Diseases; Pathologic Processes; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Disease Attributes; Neoplasms by Histologic Type; Uterine Diseases; Genital Diseases, Female; Neoplasms, Glandular and Epithelial; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Gonadal Disorders; Carcinoma; Uterine Neoplasms; Ovarian Neoplasms; Recurrence; Adenocarcinoma; Endometrial Neoplasms; Carcinoma, Endometrioid; Investigative Techniques; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Surgical Procedures, Operative; Cytological Techniques; Biopsy; Cytodiagnosis; Diagnostic Techniques, Surgical; Urogenital Surgical Procedures; Gynecologic Surgical Procedures; Lymph Node Excision; Endocrine Surgical Procedures; Castration; Sentinel Lymph Node Biopsy; Hysterectomy; Ovariectomy
• Other Study ID Numbers: PA12-0550 (Other Identifier: M D Anderson Cancer Center); NCI-2020-07548 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No